Lacidipine-13C4

Lacidipine-13C4 is 13C labeled Lacidipine (HY-B0347) . Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) [1][2].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Calcium Channel; Caspase; Isotope-Labeled Compounds; Reactive Oxygen Species (ROS)

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; Others

Applications

Neuroscience-Neurodegeneration

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/lacidipine-13c4.html

Solubility

10 mM in DMSO

Smiles

O=[13C]([13C]1=C(C)NC(C)=[13C]([13C](OCC)=O)C1C2=CC=CC=C2/C=C/C(OC(C)(C)C)=O)OCC

Molecular Formula

C22 13C4H33NO6

Molecular Weight

459.51

References & Citations

[1]Zhang A, et al. Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem. 2013;32 (4) :1040-9. |[2]Cristofori P, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000 Oct;18 (10) :1429-36. |[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.